Last September, Gilead made the unexpected move of launching authorized generics to its blockbuster hepatitis C drugs Epclusa and Harvoni, well before their patients expire. Now the copycats have ...
Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa. The Big Biotech is turning to TV again to promote its hep C franchise, this ...
Some Medicare Part D plans did not cover generic versions of pricey hepatitis C drugs in 2019, leaving millions in savings on the table, according to a new watchdog report. The report, released ...
Gilead Sciences' plan to sell lower-priced generic versions of chronic hepatitis C treatments Harvoni and Epclusa has raised provider hopes that the move will accelerate state efforts to improve ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results